Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients.

"We have built mutual trust and respect over the years in the CAR T industry and this collaboration will be the starting point for a long-term partnership. Our mission at Allogene is to catalyze the next revolution in cancer treatment through the development of allogeneic CAR T therapies directed at blood cancers as well as solid tumors. We believe this collaboration fuels our mission and we look forward to partnering with Cellectis to accelerate the development of allogeneic cell therapies.”

David Chang, M.D., Ph.D., President and Chief Executive Officer of Allogene

Servier is the leading French independent pharmaceutical company. Cellectis and Servier are collaborating on next generation gene-edited allogeneic CAR T-cell products targeting CD19.

"Collaborating closely with Cellectis on UCART19, an innovative cellular therapy candidate against lymphoid malignancies, Servier’s team constantly explores new horizons and delivers the utmost best of their expertise. Together, our highly complementary competencies and know-how give our teams the best chances of providing patients worldwide with a new generation of cancer treatments they need."

                Olivier Laureau, President of Servier

Iovance is a late-stage biotechnology company developing novel T-cell-based cancer immunotherapies. Cellectis and Iovance have a research collaboration and exclusive worldwide license agreement whereby Iovance licenses certain TALEN^® technology from Cellectis in order to develop tumor infiltrating lymphocytes (TIL) that have been genetically edited to create more potent cancer therapeutics.

“We are very excited to be collaborating with Cellectis in applying the TALEN® gene-editing technology to Iovance’s TIL product. We believe that we can genetically modify TIL to make a more tumor-reactive anti-cancer product. We plan to move a TALEN^®-edited TIL therapy into a clinical trial as rapidly as possible.”

Maria Fardis, Ph.D., MBA, President and Chief Executive Officer of Iovance Biotherapeutics.

The University of Minnesota granted Cellectis an exclusive license to TALEN® gene editing technology. TALEN® enables the ability to rethink how we treat diseases altogether. Cells can be engineered with optimized features for cancer therapies, drug discovery, gene function studies, industrial biotechnology and more.